CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities:
Net income (loss)	$ 38,162	$ (10,936)	$ 117,699
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	26,039	23,847	24,935
Non-cash compensation	30,639	29,024	16,560
Amortization and impairment of operating lease right of use assets	34,422	33,996	46,029
(Gain) loss on disposal of property and equipment	(28)	319	519
Gain on deconsolidation of joint venture	(1,626)	0	0
Deferred income taxes	7,416	20,655	23,377
Loss on personal care divestiture	0	2,186	0
Merger termination fee	0	106,000	0
Equity in (earnings) loss from equity method investments	(6,267)	(10,760)	45
Amortization of deferred debt issuance costs	991	991	991
Return on equity method investments	3,631	5,073	5,163
Impairment	48,391	0	3,009
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	16,477	(26,727)	(14,230)
Other current assets	11,700	(6,638)	(3,525)
Operating lease right of use assets	(4,196)	(3,786)	(3,242)
Other assets	744	189	438
Accounts payable	12,210	(15,816)	4,894
Accrued expenses	33,066	23,694	(39,382)
Other long-term obligations	(536)	(3,390)	(8,822)
Operating lease liabilities	(29,570)	(30,733)	(41,175)
Net cash provided by operating activities	221,665	137,188	133,283
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	55	54	252
Proceeds from the sale of property and equipment	0	136	66
Purchases of property and equipment	(6,550)	(5,620)	(6,165)
Investments in technology assets	(823)	(7,093)	(1,050)
Investment in equity method investee	(1,046)	0	(637)
Purchase of cost method investment	0	0	(15,000)
Return of investment	0	150	0
Proceeds from personal care divestiture	0	47,787	0
Acquisitions of businesses, net of cash acquired	0	(350)	(71,952)
Net cash (used in) provided by investing activities	(8,364)	35,064	(94,486)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	309	100	2,304
Proceeds from issuance of stock to employee stock purchase plan	0	2,602	3,848
Shares withheld to pay taxes on non-cash compensation	(6,152)	(6,529)	(7,981)
Noncontrolling interest contributions	2,212	1,452	3,501
Noncontrolling interest distributions	(3,362)	(1,873)	(1,561)
Proceeds from sale of noncontrolling interest	0	0	5,817
Proceeds from borrowings under revolving line of credit	0	23,000	534,500
Repayments of borrowings under revolving line of credit	0	(23,000)	(534,500)
Principal payments of long-term obligations	(37,357)	(76,013)	(13,296)
Purchase of company stock	0	0	(17,351)
Payment of accrued contingent consideration	(4,572)	(6,461)	(5,714)
Purchase of noncontrolling interest	0	(800)	0
Net cash used in financing activities	(48,922)	(87,522)	(30,433)
Net increase in cash, cash equivalents and restricted cash	164,379	84,730	8,364
Cash, cash equivalents and restricted cash at beginning of period	138,863	54,133	45,769
Cash, cash equivalents and restricted cash at end of period	303,242	138,863	54,133
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	29,989	29,766	14,939
Cash Paid For Infinity ZPIC Interest	0	0	12,755
Cash paid for income taxes, net of refunds received	40,095	29,127	24,013
Accrued contingent consideration	0	0	19,195
Noncontrolling interest contribution	$ 0	$ 0	$ 8,900